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The association between changes in systolic and diastolic
blood pressure, and the use of cardioprotective drugs on
survival of incident hemodialysis patients, was examined in
this retrospective cohort study. Pre-hemodialysis systolic and
diastolic blood pressures were averaged over the first month
of hemodialysis. Slopes, reflecting temporal changes, were
computed by linear regression of systolic blood pressures
and Cox regression was used for survival analyses. Patients
were initially stratified into four cohorts (below 120, 120
to 150, 151 to 180, and above 180mmHg) and further
subdivided into groups with stable (no more than a 1-mmHg
change per month), increasing (over 1-mmHg per month),
and decreasing (less than 1-mmHg per month) slopes during
the first year. Analyses were repeated for patients who
were treated with cardioprotective drugs for 1 month or
more in the second year. In 10,245 patients (59% prescribed
cardioprotective drugs), both increases and decreases
in all ranges of blood pressure were associated with
worse outcomes, whereas stable blood pressure had a
survival advantage at all levels of systolic and diastolic
pressures. Use of cardioprotective drugs attenuated changes
and improved survival. Validation and sensitivity analyses
confirmed the primary findings. Therefore, previous temporal
trends need to be considered in patient care, and the use
of cardioprotective agents is associated with enhanced
survival at all blood pressure levels.
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In the general population, a strong association exists between
elevated systolic and diastolic blood pressure (SBP, DBP) and
mortality.1 A recent meta-analysis showed that lower SBP and
DBP are associated with a lower risk for stroke and ischemic
heart disease at all ages.2
In the majority of hemodialysis patients, predialysis
BP measurements are above normal ranges.3,4 The Kidney
Disease: Improving Global Outcomes recently reviewed
current views, and concluded hypertension to be ubiquitous
in this population, and suggested the general use of cardio-
protective drugs (CPD).5 Kidney Disease Outcomes Quality
Initiative recommends, without evidence from randomized
controlled trials, BP goals below 140/90 before hemodialysis
and 130/80 mm Hg after hemodialysis.6
Similar to the general population,7–15 in hemodialysis
patients the relationship between BP and mortality is
U-shaped in hemodialysis patients.16–18 Deviations of BP
levels associated with favorable outcomes in hemodialysis
patients as compared with those in the general population
have not been satisfactorily explained. It is remarkable that
most studies consider the patients’ average BP level as the key
prognosticator, ignoring temporal trends and the potential
impact of changes in BP.
This observational cohort study (www.clinicaltrials.gov:
#NCT01330004) examined the evolution and temporal
changes in SBP and DBP of incident patients over the first
year of dialysis and repeated the analysis in the subsequent
year for survivors to test the hypothesis that both increases
and decreases in BPs associate with higher mortality. The
secondary aim of the study was to test the hypothesis that
the use of CPD influences BP changes and also associates
with better survival.
RESULTS
Demographics
The study population included 12,695 incident hemodialysis
patients, with 10,245 patients who underwent an average
of 94±37 treatments in Year 1 meeting inclusion criteria
(Figure 1). Demographics are shown in Table 1.
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Blood pressure
Table 2 shows SBP and DBP during the first 30 days, and the
respective slopes of patients with stable, decreasing, and
increasing SBP after initiation of dialysis (see Figure 2 for the
distribution of SBP in the studied cohort). With CPD pres-
cription, both decreases and increases in SBP were attenu-
ated, (Figure 3) and multivariable linear regression (LR) with
SBP slope as the dependent variable showed that the use of
CPD had an impact on the slope in patients with increasing
(b 0.06, Po0.01) and decreasing (b 0.03, Po0.01) slope
(data not shown). Stratification of patients into categories
of (1) stable SBP and (2) increase (45 mm Hg per month)
and (3) decrease (less than 5 mm Hg per month) indicated
that patients with stable SBP were more likely to be on CPD
(Table 3), which is consistent with the initial findings. Effects
of CPD on DBP were similar but less pronounced.
Survival analysis
Crude mortality and normalized mortality rates (per 1000
patient-years) after the initiation of hemodialysis differed
between the groups (Table 4). Cox proportional hazard
analysis (Table 5) demonstrated that within baseline BP
categories patients with a SBP below 120 mm Hg had the
worst survival, and patients with SBP in the range of 151–180
(reference group) the best survival (Figure 4). However,
longitudinally, survival was highest in patients with stable
SBP independent of SBP level. Patients with decreasing SBP
exhibited the worst survival, which was most pronounced in
the lowest SBP range. Survival was also poor in patients with
SBP increase (Figure 4). Similar findings were obtained in the
analysis of DBP (Figure 5). The use of CPD had a favorable
impact on survival (Table 5).
Sensitivity analyses
For the first sensitivity analysis, only data of patients with
slopes showing P-values below 0.05 were included (n¼ 8395).
The result of this survival analysis was consistent with the
original analyses; thus, the analysis did not appear to be
confounded by the certainty of the slope computation.
For the second sensitivity analysis, the first and last six
SBP measurements were excluded, with the results remaining
consistent with the original analyses. Slope computation did
not appear to be confounded by outliers at the beginning or
end of the observation period.
For the third sensitivity analysis, patients with the largest
changes in SBP were excluded. The relationship between
changes in SBP and mortality remained the same in this
analysis.
The fourth sensitivity analysis defined patients with stable,
increasing, and decreasing SBP according to the upper and
lower, respectively, limits of their 95% confidence interval,
with results similar to the primary analysis.
Validation of survival analysis
In a subset validation analysis (Figure 6), changes of SBP
in patients with CPD therapy (initiating hemodialysis after
2008), and those in whom CPD was not being prescribed
(initiating hemodialysis before 2006), showed, consistent
with the initial findings, that patients on CPD were more
likely to have stable BP and thus better outcome. The positive
effect of the quality initiative on patients’ survival is also
illustrated in a Kaplan–Meier survival analysis (Figure 7).
Repetition of survival analysis with seasonality as an adjust-
ment factor did not materially change the results as compared
with the main analysis (Figure 8). In all, 6067 (at this point
Patients who started in-center hemodialysis treatment in RRI/NYDS clinics within 30 days of their first-ever
dialysis treatment between 1 January 2000 and 28 February 2010,  
N =12,695
No available data on date of birth, race,
gender, ethnicity, diabetic status,
N =278 N =1593
N =579
<13 Treatments in the first year of dialysis,
Last treatment within >30 days prior to
death or discharge in Year 1,
Patients included in Year 1 analysis,
N =10,245
Patients included in Year 2 analysis,
Transfer to another clinic, transplanted, other
discharge reasons,
N = 3121
Died,
N =1057
N = 6067
Died,
N = 542
Figure 1 | Study flowchart.
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Figure 2 |Histogram of systolic blood pressure (SBP) change
per month of patients in all ranges of SBP.
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prevalent) hemodialysis patients were included in the analysis
in Year 2. Results of survival analysis according to SBP
categories and temporal changes in Year 2 (Figure 9) were
consistent with the results in Year 1 (Figure 4). Similar anal-
ysis of the relationship of temporal changes in SBP relative to
all levels of SBP (producing hazard ratios for cardiovascular
mortality) reflected findings similar to the primary analysis
(Figure 10).
DISCUSSION
To the best of our knowledge, this is the first observational
cohort study in a large group of incident hemodialysis
patients that evaluates the association of absolute SBP and
DBP levels and subsequent temporal BP changes to mortality
over a period of 1 year. The main findings indicated that
mortality in the first year on hemodialysis was greater in
patients with both decreases or increases in BP relative to
stable BP, independent of absolute BP levels (Figures 4
and 5); this result remained consistent in Year 2 (compare
Figures 4 and 9).
Temporal changes in both SBP and DBP, rather than the
BP category, had greater impact on survival (Figure 4).
Furthermore, our findings suggest a potential beneficial effect
of using CPDs in potentially stabilizing temporal BP changes
over time and improving survival.
The explanation of these findings may reflect two different
operative vectors: one, the decreasing BP due to failure of
ventricular function and thus a marked increase in mortality,
and the second is increasing BP, for reasons that remain to be
Table 3 | Change of SBP in patients with active prescription of
CPD and without, after stratification in patients with (1)
stable SBP and (2) increase (45mmHg per month) and (3)
decrease (less than 5mmHg per month) of SBP
SBP (change per month) Not on CPD (%) On CPD (%)
Declined (less than 5) 13.8 9.8
Stable (1 to 1) 72.0 79.9
Increased (45) 14.1 10.3
Abbreviations: CPD, cardioprotective drug; SBP, systolic blood pressure.
Table 4 |Number of deaths and mortality rates in all patients (N=10,245) and in patients in the different categories of SBP and
SBP change (decline, stable, and increase)
SBP change Deaths (count) Exposure time (days) Mortality rate (n/1000 patient-years)
SBPo120mmHg Decline (N=208) 94 39,011 880.10
Stable (N=320) 28 99,421 102.87
Increase (N=432) 79 104,945 274.95
All patients (N=960) 201 243,377 301.65
SBP 120–150mmHg Decline (N=1224) 226 316,199 261.06
Stable (N=1735) 86 569,950 55.11
Increase (N=1869) 202 505,238 146.03
All patients (N=4828) 514 1,391,387 134.93
SBP 151–180mmHg Decline (N=1535) 159 433,736 133.89
Stable (N=1295) 47 427,963 40.11
Increase (N=978) 76 261,933 105.98
All patients (N=3808) 282 1,123,632 91.67
SBP4180mmHg Decline (N=382) 46 112,594 149.22
Stable (N=181) 7 60,411 42.32
Increase (N=86) 7 22,184 115.25
All patients (N=649) 60 195,189 112.28
All patients (N=10,245) 1057 2,953,585 130.71
Abbreviation: SBP, systolic blood pressure.
Table 5 | Cox proportional hazards model for survival analysis
in Year 1
Hazard ratio (95% CI) P-value
SBPo120mmHg, declined 8.375 (5.805–12.084) o0.0001
SBPo120mmHg, stable 1.344 (0.835 – 2.164) 0.223
SBPo120mmhg, increased 3.594 (2.483–5.202) o0.0001
SBP 120–150mmHg, declined 3.731 (2.700–5.156) o0.0001
SBP 120–150mmHg, stable 1.099 (0.766–1.578) 0.607
SBP 120–150mmHg, increased 2.678 (1.937–3.702) o0.0001
SBP 151–180mmHg, declined 2.634 (1.893–3.665) o0.0001
SBP 151–180mmHg, stable Reference group
SBP 151–180mmHg, increased 2.516 (1.743–3.632) o0.0001
SBP4180mmHg, declined 3.344 (2.213–5.053) o0.0001
SBP4180mmHg, stable 1.125 (0.507–2.497) 0.773
SBP4180mmHg, increased 2.995 (1.349–6.650) 0.007
Age (years) 1.028 (1.023–1.033) o0.0001
Male (yes/no) 1.146 (1.009–1.301) 0.036
Race—white (yes/no) 1.260 (1.090–1.458) 0.002
Ethnicity—Hispanic (yes/no) 0.713 (0.564–0.900) 0.004
COPD (yes/no) 0.576 (0.391–0.848) 0.005
Drug/alcohol (yes/no) 0.552 (0.244–1.249) 0.154
Hepatitis (yes/no) 1.970 (0.812–4.778) 0.134
Hyperparathyroidism (yes/no) 0.588 (0.277–1.246) 0.166
Infection (yes/no) 0.456 (0.262–0.796) 0.006
CPD therapy (yes/no) 0.717 (0.630–0.815) o0.0001
Albumin (g/dl) 0.162 (0.145–0.181) o0.0001
IDWG (% post-HD body weight) 0.926 (0.866–0.990) 0.023
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease;
CPD, cardioprotective drug; HD, hemodialysis; IDWG, interdialytic weight gain;
SBP, systolic blood pressure.
Covariables (not related to blood pressure) with P-value in the model larger than 0.2
are not shown (Asian race, diabetes, pre-existing anemia, cancer, arrhythmias,
cerebrovascular disease, congestive heart failure, gastrointestinal bleed, human
immunodeficiency virus or acquired immunodeficiency syndrome, ischemic heart
disease, myocardial infarction or cardiac arrest, peripheral arterial or venous disease,
pneumonia, and body mass index).
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fully determined, but likely includes salt and fluid overload,
with a lesser effect on mortality than in those with declining
blood pressure. In addition, it is noteworthy that many
comorbidities and laboratory parameters lost significance
in the Cox proportional hazard model after inclusion of
temporal changes of SBP and also with the use of CPD. It is
well known that cardiovascular disease is the leading cause of
death in this population, but the extent to which temporal
changes of SBP appear to influence survival in this analysis is
quite remarkable (Table 5, Figure 4).
SBP < 120, declined
HR LCL UCL
8.38 5.81 12.08
1.34 0.84 2.16
3.59 2.48 5.20
3.73 2.70 5.16
1.10 0.77 1.58
2.68 1.94 3.70
2.63 1.89 3.67
1.001.001.00
2.52 1.74 3.63
3.34 2.21 5.05
1.13 0.51 2.50
3.00 1.35 6.65
SBP < 120, stable
SBP < 120, increased
SBP 120 – 150, declined
SBP 120 – 150, stable
SBP 120 – 150, increased
SBP 151 – 180, declined
SBP 151 – 180, stable
SBP 151 – 180, increased
SBP >180, increased
0 1 2 3 4 5 6 7 8 9
Hazard ratio (95% confidence interval)
10 11 12 13 14 15
SBP > 180, declined
SBP > 180, stable
Figure 4 | Forest plot of levels of systolic blood pressure (SBP) and temporal changes (reflected by changes in slope), and its
relationship with hazard ratio for death in all 12 groups. Data are presented as hazard ratio (HR) and 95% confidence interval
(lower confidence limit (LCL) to upper confidence limit (UCL)).
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Figure 5 | Forest plot of levels of diastolic blood pressure (DBP) and temporal changes (reflected by changes in slope), and its
relationship with hazard ratio (HR) for death in all 12 analyzed groups. Data are presented as HR and 95% confidence interval
(lower confidence limit (LCL) to upper confidence limit (UCL)).
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The favorable effect of CPD in improving mortality
both in patients with decreasing and increasing BP was
unexpected, although it is consistent with reported cardio-
protective effects of CPD demonstrated in the few long-
term randomized trials performed in hemodialysis patients.
Extensive meta-analyses have shown that reduced mortality
risk was observed in patients on CPD without substantial
BP change.19,20 In this analysis, calcium channel blockers
were not included, although their use has been reported
to reduce mortality.21 However, because of the lack of data
from randomized controlled trials on the cardioprotective
effect of this drug class in dialysis patients, it was elected to
not be included in this analysis.
Relative to other BP categories, CPD use is associated with
a smaller decrease in BP in patients with baseline levels of
below 120 mm Hg. This could be the result of medication
effects counteracting the adverse consequences of progressive
cardiomyopathy. In patients with increase in BP, the
subsequent reduction in BP by CPD is compatible with
antihypertensive effects of CPD.
All Year 2 analyses of survival were consistent with that of
Year 1 (compare Figures 4 and 9). This confirmatory test of
our basic argument also affirms the continued favorable
effect of CPD in all patients at risk. This is further supported
by the results of the quality initiative (Figure 7).
A major strength of this analysis is the large sample size
and the balanced distribution of patients in all analyzed
patient groups (Table 1). Patients of 51 different dialysis
clinics in different states and geographical regions were
included in this observational cohort study. This widespread
patient population and the large sample size improve
generalizability to the United States hemodialysis population.
Selection of incident patients allowed the study of the
evolution of BP virtually with considerably little effect of
hemodialysis treatment at study baseline (defined as the first
month after the first hemodialysis treatment) and after
initiation of hemodialysis, with its effects on the cardiovas-
cular system.
The repetition of the survival analysis in Year 2 (n¼ 6067)
diminishes survival bias often encountered in analyses of
prevalent chronic hemodialysis patient cohorts. In addition,
this observational study allowed analysis of a prevalent
patient population with exactly the same hemodialysis
vintage (compare Figures 4 and 9). Similar relationships
between cardiovascular mortality and temporal evolution of
SBP (Figure 10) confirm the reliability of our findings. The
sensitivity analysis with exclusion of patients in the highest
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Figure 6 | Subset validation analysis to validate the
relationship between therapy with cardioprotective drugs
(CPDs) and (a) decreases and (b) increases in systolic
blood pressure (SBP). Patients included in the subset were
those initiating dialysis before 2006 and were not on CPD,
and patients who started dialysis after a CPD quality initiative
in 2007 and who had an active CPD prescription. CI, confidence
interval.
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Figure 7 |Kaplan–Meier survival curves in two subsets of
patients: (1) those who initiated hemodialysis before 2006
and were not on cardioprotective drugs (CPDs), and (2) those
who started hemodialysis after a quality initiative
(suggesting use of CPD in all patients regardless of blood
pressure) in 2007 and were on CPD.
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quartiles of BP change indicated that the results were not
driven by a few patients with extreme changes of SBP.
The sensitivity analysis using univariable LR to estimate
the slope for every individual patient was further validated by
narrowing the criteria for defining patients as stable, and
including only patients whose SBP slope increased and
decreased significantly. The latter method confirmed that
outlier measurements did not influence the results. The
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Figure 8 |Validation analysis: Forest plot of levels of systolic blood pressure (SBP) and temporal changes (reflected by changes
in slope), and its relationship with hazard ratio (HR) for death in all 12 groups after adjustment for season of death or season of
end of Year 1 in survivors (spring, summer, autumn, and winter). Data are presented as HR and 95% confidence interval (lower
confidence limit (LCL) to upper confidence limit (UCL)).
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Figure 9 |Validation analysis: Forest plot of levels of systolic blood pressure (SBP) and temporal changes (reflected by changes in
slope) in Year 2, and its relationsip with hazard ratio (HR) for death in all 12 groups. Data are presented as HR and 95% confidence
interval (lower confidence limit (LCL) to upper confidence limit (UCL)).
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second sensitivity analysis, which excluded the first and last
six SBP measurements in the observation period, also
indicated that the findings were not confounded by outliers.
The third and the fourth sensitivity analyses confirmed the
statistical validity of our approach and supported the
hypothesized biological phenomena. Further, survival ana-
lyses with adjustment for season (Spring, Summer, Autumn,
and Winter) of death (or end of Year 1 for survivors)
excluded potential confounding by seasonal differences of
mortality (Figure 8).
Limitations of the analysis included the absence of
information on SBP before initiation of hemodialysis, which
would have been of interest when investigating the temporal
evolution subsequent to hemodialysis initiation. Lack of
information of the degree of hydration status was another
limitation, which is difficult to overcome with current
technologies.22 Knowledge of cardiac function and structure
by cardiac magnetic resonance imaging or echocardiography
would have provided information on cardiac structure and
function that could confirm postulated reasons for the
decrease or increase in SBP. The use of different BP measure-
ment methods, such as home or ambulatory methods, may
have been preferable, but even these methods are, to a degree,
difficult to interpret in a hemodialysis population, because of
the increase in volume and BP, which occurs progressively
during the interdialytic interval. Although the measurements
of predialysis and postdialysis BPs are imprecise,23 their
frequent measurement and the relationship between levels
and outcomes provide reassurance. Another consideration
may be that the analysis of CPD could be confounded by
treatment with indication biases, although this was mini-
mized by (1) the large sample size included in this analysis
and (2) the subset validation analysis comparing patients
initiating dialysis before 2004 as compared with those
starting dialysis after 2007 (Figures 6 and 7). An additional
concern is a potential bias induced by varying duration of
CPD prescription, as this parameter was not captured in this
analysis. Several limitations also exist on the documentation
of comorbidities and CPD. The latter, in particular, includes
the following: (1) the lack of knowledge on dose and
frequency of CPD, (2) the dependence on the accuracy of the
administrative staff on the documentation of drugs prescrip-
tions, and (3) the possibility of erratic patient adherence.
However, with the methods of analysis used, none of these
issues are likely to cause any systematic error or bias
(compare Figures 3 and 6).
Future analyses are needed to elucidate the relationships
between BP level, temporal changes of BP, and CPD use on
survival in patients before initiation of dialysis. Another
further major research question remains: ‘To what extent
should BP increases and decreases be managed by sodium
restriction and ultrafiltration or by the use of CPD at
different degrees of cardiac status and function’. This
question can only be answered by an adequately powered
randomized controlled trial.
In conclusion, we found that blood pressure readings are
best interpreted using prior temporal trends and should not
be taken in isolation. The clinical problem posed by these
data is that an apparently normal BP may be misinterpreted
as being satisfactory. If absolute BP values are in the normal
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Figure 10 |Validation analysis: Forest plot of levels of systolic blood pressure (SBP) and temporal changes (reflected by changes
in slope), and its relationship with hazard ratio (HR) for cardiovascular death in all 12 analyzed groups. Data are presented as HR
and 95% confidence interval (lower confidence limit (LCL) to upper confidence limit (UCL)).
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range because of cardiac decompensation, consideration of
only BP values may provide a false sense of security when a
particularly decreasing or increasing trend is not appreciated.
Evaluation of cardiac and fluid status is essential in inter-
preting blood pressure levels. The favorable effect observed
with the use of CPD and the mechanism of action requires
further evaluation in prospective clinical trials of this patient
population.
MATERIALS AND METHODS
Patient population
All patients starting in-center hemodialysis between 1 January 2000
and 31 December 2008 in 51 facilities (see Appendix) operated
by Renal Research Institute and New York Dialysis Services were
included in this analysis (www.clinicaltrials.gov: #NCT01330004).
Patients with complete demographic data (date of birth, gender, race,
ethnicity, diabetic status, and height), at least one routine laboratory
measurement, at least 13 treatments in the first year of dialysis, and
the last treatment occurring within 30 days before discharge date or
the end of Year 1 were included. Patients were monitored during
Year 1; for patients who survived Year 1, the observation time was
extended to the end of Year 2. Patients who were transferred to other
clinics, switched modality, and received a transplant were censored
for survival analysis. This observational study was approved by the
Institutional Review Board of Beth Israel Medical Center, New York.
Cohorts of SBP and DBP
SBP and DBP were measured before hemodialysis in a sitting
position after a 5-min rest period with an oscillometric method by
health-care professionals in the clinics. Average SBP and DBP were
individually computed from all treatments during the first 30 days
after dialysis initiation. Slopes of SBP and DBP change were
determined by univariable LR using all BP measurements available
in Year 1 until censoring or death.
Patients were stratified into four groups according to mean
predialysis SBP during the first month as follows: (1) below 120,
(2) between 120 and 150, (3) between 151 and 180, and (4) above
180 mm Hg. They were further stratified based on the slope of
SBP as stable (SBP slope between þ 1 and 1 mm Hg per month),
decreasing (less than 1 mm Hg per month), or increasing (more
than þ 1 mm Hg per month). This four-by-three grouping strategy
resulted in 12 analytical cohorts.
In a second analysis, patients were stratified according to mean
predialysis DBP in the first 30 days into the following: (1) below 65,
(2) between 65 and 75, (3) between 76 and 85, and (4) above
85 mm Hg. DBP categorization according to slope was carried out in
the same manner as for SBP.
Clinical parameters
Predialysis and postdialysis weights and interdialytic weight gain
were averaged from all available treatments during Year 1. Albumin
was measured using the bromocresol green method, performed by a
certified laboratory (Spectra Laboratories, Rockleigh, NJ).
Comorbid illnesses were classified according to the International
Classification of Diseases.24
Evaluation of CPDs
Angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, and b-adrenergic blockers were identified as CPDs.5,19,20
Therapy with CPD was binary coded and based on whether a patient
was prescribed either of these drugs at the start or during Year 1 of
dialysis, regardless of dose and frequency.
Sensitivity analyses
Three sensitivity analyses were conducted to exclude confounding
influences. A first sensitivity analysis defined a slope between 0.03 and
0.03 mm Hg as stable and included patients with increasing and
decreasing slopes only when showing a P-value below 0.05 for the slope
in univariable LR. Others were entirely excluded. A second sensitivity
analysis excluded the first and last six SBP measurements per patient.
This approach aimed to exclude confounding of slope computation by
outliers at the beginning and end of the observation period. A third
sensitivity analysis excluded the lowest and highest quartiles of increasing
and decreasing SBP, respectively. This aimed to exclude the possibility
that the results were driven by a small number of patients with large
changes in SBP. A fourth sensitivity analysis defined the categories of SBP
change as follows: patients with increasing SBP were only those with a
lower 95% confidence interval limit larger than 1 mm Hg, and patients
with decreasing SBP were only those with an upper 95% confidence
interval limit below1 mm Hg. Patients with stable SBP were only those
with upper 95% confidence interval limits lower than 1 mm Hg and
lower 95% confidence interval limit larger than1 mm Hg. This analysis
aimed to test the statistical validity of our approach.
Validation analyses
In 2007, Renal Research Institute instituted a quality initiative
recommending physicians to prescribe CPD to most patients.
To support the analysis of potential impact of CPD on SBP and
DBP slope and to minimize ‘treatment by indication’ bias, analyses
of BP levels and slope were compared between the subset of patients
who (1) initiated dialysis before 2006 and were not on CPD, and
(2) patients who started dialysis after the quality initiative in 2007
and were on CPD. The effect of this quality initiative on survival was
analyzed in the two subsets with Kaplan–Meier analysis to compare
death rates between patients with and without CPD therapy.
To exclude influences of seasonality, the survival analysis was
repeated with adjustment for season of death (spring, summer,
autumn, and winter) for patients who died and season of end of
Year 1 for patients who survived.
To validate findings in Year 1, all analyses were repeated in
patients who survived more than 1 month with more than
13 treatments in Year 2. Clinical parameters were determined anew
at the beginning of Year 2.
To validate that these findings are related to the changes in SBP
and not to other causes of death, the analysis of the relation
of temporal changes of SBP at all levels of SBP to hazard ratio was
repeated for cardiovascular mortality only.
Statistical analysis
Slopes of SBP and DBP were computed using univariable LR.
Multivariable LR models for patients with increasing and decreasing
SBP slopes as dependent variables were constructed to estimate the
effect of CPD on SBP change. Cox proportional hazards models
were developed to determine the relation of SBP and DBP slope to
survival. A P-value below 0.05 was considered significant. Analyses
were conducted in SPSS 18.0 (IBM, Somers, NY) and SAS 9.2
(SAS Institute, Cary, NC).
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Appendix
Patients were dialyzed at Albany Dialysis Center (NY);
Albany Regional Dialysis Center (NY); Amsterdam Dialysis
Center (NY); Atlantic Hemodialysis (NY); Bayside Dialysis
(NY); Branford Dialysis Center (CT); Bronx Center for
Nursing and Rehabilitation (NY); Brookdale Physicians
Dialysis Associates (NY); Brooklyn Kidney Center (NY);
Capital District Dialysis Center (NY); Carolina Dialysis—
Carrboro (NC); Carolina Dialysis—Pittsboro (NC); Carolina
Dialysis—Sanford (NC); Carolina Dialysis—Siler City (NC);
Central Suffolk Artificial Kidney Center (NY); Champaign-
Urbana Dialysis Center (IL); City Dialysis Center (NY);
Cobble Hill Nursing Home (NY); Dutchess Dialysis Center;
Harlem Dialysis Center; Irving Place Dialysis Center;
Michigan Dialysis—Ann Arbor (MI); Michigan Dialysis—
Livonia (MI); Middletown Dialysis Center (NY); Milford
Dialysis Center (CT); Montefiore Dialysis Center I (NY);
Montefiore Dialysis Center II (NY); Montefiore Dialysis
Center III (NY); Montefiore Dialysis Center IV (NY); Nephro
Care Inc. (NY); Nephro Care West (NY); Newport Beach
Dialysis Center (CA); Newport Mesa (CA); North Haven
(CT); Queens Artificial Kidney Center (NY); Sound Shore
Dialysis Center (NY); South Queens Dialysis Center (NY);
Southern Manhattan Hemodialysis Center (NY); Southern
Westchester Hemodialysis Center (NY); St Alban’s Dialysis
(NY); St Raphael’s Dialysis (NY); Clinton Crossing Unit
(NY)*; Finger Lakes Unit (NY)*; Highland Self Care Unit
(NY)*; Living Center Unit (NY)*; Strong Memorial Hemo
Program (NY)*; Upper Manhattan Dialysis Center (NY);
Western New York Artificial Kidney Center—Buffalo
(NY); Western New York Artificial Kidney Center—Kenmore
(NY); Western New York Artificial Kidney Center—Niagara
Falls (NY); Yorkville Dialysis Center (NY). Dialysis
facilities indicated with an asterisk are part of Strong Health
Dialysis.
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